The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 5, 1999, Pages 1143-1149

  Movsas, Benjamin ^a   Scott, Charles ^b   Sause, William ^c   Byhardt, Roger ^d   Komaki, Ritsuko ^e   Cox, James ^e   Johnson, Douglas ^f   Lawton, Colleen ^d   Dar, A Rashid ^g   Wasserman, Todd ^h   Roach, MacK ⁱ   Lee, J S ^e   Andras, Ellis ^j  

^a FOX CHASE CANCER CENTER   (United States)

^b RTOG Headquarters   (United States)

^c LDS HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Baptist Cancer Institute   (United States)

^g LONDON REGIONAL CANCER PROGRAM   (Canada)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Radiation Oncology Center   (United States)

more..

Author keywords

Age; Chemoradiation; Histology; Locally advanced non small cell lung cancer; Quality adjusted survival

Indexed keywords

CISPLATIN; ETOPOSIDE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER SURVIVAL; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ETOPOSIDE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 0032794019     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00325-9     Document Type: Article

References (23)

1. Murray K.J., Nelson D.F., Scott C., et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine A report of Radiation Therapy Oncology Group (RTOG) 83-02 . Int J Radiat Oncol Biol Phys. 31:1995;453-459.
2. Scott C.B., Movsas B., Sause W., et al. Intensified treatment increases survival in patients with non-small cell lung cancer (NSCLC) at what price? A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies. Quality of Life Research. 6:1997;718.
3. Cox J.D., Azarnia N., Byhardt R., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 Gy to 792 Gy Possible survival benefit with ≥ 69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung carcinoma: Report of RTOG 83-11 . J Clin Oncol. 8:1990;1543-1553.
4. Sause W.T., Scott C., Taylor S., et al. Radiation therapy oncology group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
5. Sause W.T., Scott C., Taylor S., et al. Phase II trial of combination chemotherapy and irradiation in nonsmall cell lung cancer. Radiation Therapy Oncology Group 88-04. Am J Clin Oncol. 15:1992;163-167.
6. Byhardt R., Scott C., Ettinger D., et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer. Cancer. 75:1995;2337-2344.
7. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer Radiation Therapy Oncology Group Protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
8. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer Radiation Therapy Oncology Group (RTOG) 92-04 . Int J Radiat Oncol Biol Phys. 38:1997;149-155.
9. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;134-136.
10. Scott C.B. Quality-adjusted survival analysis of malignant glioma patients. Controlled Clin Trials. 18:1997;277-285.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
12. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1992;1618-1624.
13. Quon H., Shepherd F.A., Payne D.G., et al. The influence of age on the delivery tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 43:1999;39-45.
14. Komaki R., Scott C., Sause W., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer (SCC) Failure patterns by cell type in RTOG 88-08/ECOG 4588 . Int J Radiat Oncol Biol. 39:1997;537-544.
15. Komaki R., Cox J.D., Stark R. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung Correlation with survival . Int J Radiat Oncol Biol Phys. 9:1983;1467-1470.
16. Konski A., Bracy P., Weiss S., et al. Cost-utility analysis of a malignant glioma protocol. Int J Radiat Oncol Biol Phys. 39:1997;575-578.
17. Croog S.H. Current issues in conceptualizing and measuring quality of life. In Quality of life assessment Practice, problems and promise . NIH. 1993;11-20. (NIH Publication no. 93-3503).
18. Cox D.R., Fitzpatrick R., Fletcher A.E., et al. Quality-of-life assessment Can we keep it simple? J Roy Stat Soc A. 155:1992;353-393.
19. Smith A. Qualms about QALY's. Lancet. 1:1987;1134-1136.
20. Montazeri A., Milroy R., Gillis C.R., et al. Quality of life Perception of lung cancer patients . Eur J Cancer. 32A:1996;2284-2289.
21. de Haes J.C., de Koning H.J., van Oortmarssen G.J., et al. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Radiat Oncol Biol Phys. 49:1991;538-544.
22. Brundage M.D., Groome P.A., Feldman-Stewart D., et al. Decision analysis in locally advanced non-small cell lung cancer Is it useful? J Clin Oncol. 15:1997;873-883.
23. Gower N.H., Rudd R.M., Ruiz de Elvira M.C., et al. Assessment of "quality of life" using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol. 6:1995;575-580.